TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2147775

Group type: EXPERIMENTAL
Intervention: Intervention programme aimed at improving personal control and social activation over 24 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study: 7014886

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil and levamisole
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 72
Study: 31793699

Group type: EXPERIMENTAL
Intervention: Provider-derived option labels
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Industry-derived option labels
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (no specific label set mentioned)
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: All option labels
Number of subjects: 1062
Study: 30545562

Group type: EXPERIMENTAL
Intervention: Pediatric Rhinosinusitis Symptom Scale (PRSS)
Number of subjects: 258
Study: 29187135

Group type: EXPERIMENTAL
Intervention: Intensive LDKT education (n = 249) consisting of a 25-minute video and discussion with an educator.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Usual care education (n = 250).
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Intensive LDKT education (n = 249) for patients without a potential living donor.
Number of subjects: 499

Group type: COMPARATOR
Intervention: Usual care education (n = 250) for patients without a potential living donor.
Number of subjects: 499
Study: 25910710

Group type: EXPERIMENTAL
Intervention: Multimodal intervention composed of speech sound practice and augmentative and alternative communication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study: 23331339

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 21323779

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 840

Group type: COMPARATOR
Intervention: Postal questionnaire
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Telephone interview and Postal questionnaire
Number of subjects: 840
Study: 19476402

Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg taken on two consecutive days each month (2CDM)
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Risedronate 5 mg taken once daily
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg 2CDM
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Risedronate 75 mg 2CDM and Risedronate 5 mg once daily
Number of subjects: 1229
Study: 17969893

Group type: EXPERIMENTAL
Intervention: Zhiling Capsule (ZLC)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Pingxiao Capsule (PXC)
Number of subjects: 400
Study: 15110417

Group type: EXPERIMENTAL
Intervention: Cognitive factors
Number of subjects: 10650

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 10650

Group type: COMPARATOR
Intervention: SES (socioeconomic status)
Number of subjects: 10650
Study: 11806862

Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg administered by inhalator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 9512232

Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 61
Study: 8874977

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ketoconazole (200 mg/day)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 143
Study: 2328750

Group type: EXPERIMENTAL
Intervention: 750 mg metamizol sodium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1500 mg metamizol sodium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3000 mg metamizol sodium
Number of subjects: 15
Study: 7307999

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally in delay‐action form and 5 mg sublingually)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dihydralazine (75 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (three times 20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prazosin (three times 2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dihydralazine (three times 75 mg)
Number of subjects: 16
Study: 30994090

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (9.0 × 10^5 sporozoites, three doses)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (9.0 × 10^5 sporozoites, one dose)
Number of subjects: 93
Study: 28554455

Group type: EXPERIMENTAL
Intervention: Skeletally anchored facemasks anchored with miniplates placed at the zygomatic buttress (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Class III elastics extending from infrazygomatic miniplates in the maxilla to symphyseal miniplates in the mandible (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group (Group 3)
Number of subjects: 30
Study: 25741795

Group type: EXPERIMENTAL
Intervention: Web-based guided self-help intervention
Number of subjects: 231

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 231
Study: 23098695

Group type: EXPERIMENTAL
Intervention: Penetrating needles
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Skin-touch placebo needles
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-touch control needles
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall subjects' guesses
Number of subjects: 80
Study: 21070456

Group type: EXPERIMENTAL
Intervention: BoNTA injections
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 100
Study: 18377608

Group type: EXPERIMENTAL
Intervention: Smoke from burnt leaves of Populus euphratica (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional cryotherapy (Group B)
Number of subjects: 60
Study: 16298237

Group type: EXPERIMENTAL
Intervention: 99mTc‐ECD SPECT and memory scores
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hypoperfusion pattern from 99mTc‐ECD SPECT
Number of subjects: 31
Study: 12670465

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purine analogues (2-deoxycoformycin and 2-chlorodeoxyadenosine)
Number of subjects: 0
Study: 10914804

Group type: EXPERIMENTAL
Intervention: Polydioxanon barrier (test)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate (control)
Number of subjects: 21
Study: 8678514

Group type: EXPERIMENTAL
Intervention: 5-FU 10 mg/kg/24 hrs c.i.v. x 24 days (arm A, n = 25)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5-FU 20 mg/kg/24 hrs c.i.v. x 4 days/w x 3 courses (arm B, n = 16)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5-FU 30 mg/kg/24 hrs c.i.v. x 2 days/w x 4 courses (arm C, n = 25)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Modified arm B (4 days-on, 6 days-off)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study: 1769473

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Endoscopic Sclerotherapy
Number of subjects: 76
Study: 7043340

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30666732

Group type: EXPERIMENTAL
Intervention: MgSO4 50% solution (MSS at 40 mg/kg BW)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 5% dextrose solution (DS; control solution at 2 mL/kg body weight)
Number of subjects: 6
Study: 27521509

Group type: EXPERIMENTAL
Intervention: Exercise (cycling and resistance training) 3 times per week for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 24
Study: 26296190

Group type: EXPERIMENTAL
Intervention: Clavicle brace
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no brace)
Number of subjects: 30
Study: 24603102

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg daily)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 23181920

Group type: EXPERIMENTAL
Intervention: Motivation and peer social support
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Motivation and parent social support
Number of subjects: 1421
Study: 19483659

Group type: EXPERIMENTAL
Intervention: MEDI-534 vaccine (10 median tissue culture infectious dose50)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17634081

Group type: EXPERIMENTAL
Intervention: Patch test with a dilution series of 19 concentrations, duration up to 21 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Repeated open application test (ROAT) with a dilution series of three concentrations, duration up to 21 days
Number of subjects: 20
Study: 15353095

Group type: EXPERIMENTAL
Intervention: Ethical Will (EW)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 11286826

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CT) with cisplatin 60 mg/m² and epirubicin 110 mg/m² followed by radiotherapy (RT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CT) with cisplatin and epirubicin
Number of subjects: 179
Study: 9885030

Group type: EXPERIMENTAL
Intervention: Three months intensive training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Home exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 8011248

Group type: EXPERIMENTAL
Intervention: Foscarnet at a dose of 60 mg/kg every 8 h for 14 days followed by maintenance doses of 60 or 90 mg/kg/day.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Foscarnet at a maintenance dose of 120 mg/kg/day.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Foscarnet therapy compared to historic controls who terminated ganciclovir therapy.
Number of subjects: 156
Study: 3192364

Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with decongestive nose drops
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Drainage of the maxillary sinus
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Combination of amoxicillin and drainage
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 28482829

Group type: EXPERIMENTAL
Intervention: Recovery-oriented practice training intervention for specialist mental health services staff
Number of subjects: 756

Group type: COMPARATOR
Intervention: Control group (services where staff have not yet received the intervention)
Number of subjects: 756
Study: 26168365

Group type: EXPERIMENTAL
Intervention: Mindfulness in Motion (MIM) - a Mindfulness Based Intervention (MBI) delivered onsite for 1 hr/week for 8 weeks, including group sessions with gentle yoga stretches and relaxing music.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness in Motion (MIM) - a Mindfulness Based Intervention (MBI) delivered onsite for 1 hr/week for 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group (C)
Number of subjects: 0
Study: 23877228

Group type: EXPERIMENTAL
Intervention: Continuous exercise programme
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interval exercise programme
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both exercise programmes
Number of subjects: 21
Study: 21755342

Group type: EXPERIMENTAL
Intervention: 2 mg/kg aminophylline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 3 mg/kg aminophylline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 4 mg/kg aminophylline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5 mg/kg aminophylline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: aminophylline (2, 3, 4, 5 mg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: aminophylline (4, 5 mg/kg)
Number of subjects: 150
Study: 18463672

Group type: EXPERIMENTAL
Intervention: Ramipril-HCT (20 mg q.d.)
Number of subjects: 354

Group type: COMPARATOR
Intervention: HCT monotherapy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Ramipril monotherapy
Number of subjects: 354
Study: 16871533

Group type: EXPERIMENTAL
Intervention: Gout
Number of subjects: 12866

Group type: COMPARATOR
Intervention: No gout
Number of subjects: 12866

Group type: EXPERIMENTAL
Intervention: Hyperuricemia
Number of subjects: 12866
Study: 12594698

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg twice a day 24 hr before and the day of cardiac catheterization)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control (intravenous hydration alone)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control
Number of subjects: 179
Study: 10962116

Group type: EXPERIMENTAL
Intervention: Patients with CAD (n=355)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Patients with CAD with type-2 DM (n=101)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control subjects (n=100)
Number of subjects: 355
Study: 9549283

Group type: EXPERIMENTAL
Intervention: Cilostazol (150-200 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Warfarin (prothrombin time controlled to 15-25%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 16
Study: 8221800

Group type: EXPERIMENTAL
Intervention: CGRP (50 pmol.min‐1)
Number of subjects: 12
Study: 3708124

Group type: EXPERIMENTAL
Intervention: Buccal formulations
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Buffered products
Number of subjects: 26

Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Enteric coated ASA formulations
Number of subjects: 26
Study: 30229462

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Armolipid Plus® (combined lipid-lowering nutraceutical)
Number of subjects: 40
Study: 26999510

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24282157

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa-nonpurging subtype (BN-NP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Bulimia nervosa-purging subtype (BN-P)
Number of subjects: 112
Study: 23033993

Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO₂, 0.5 ppm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentrated fine particles from Chapel Hill air (PM(2.5)CAPs, 89.5 ± 10.7 µg/m³)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NO₂ + PM(2.5)CAPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 0
Study: 20409064

Group type: EXPERIMENTAL
Intervention: Web-based patient support system
Number of subjects: 149

Group type: COMPARATOR
Intervention: Leaflets
Number of subjects: 149
Study: 17609300

Group type: EXPERIMENTAL
Intervention: Cortisol withdrawal
Number of subjects: 7

Group type: COMPARATOR
Intervention: Replacement control
Number of subjects: 7
Study: 16136342

Group type: COMPARATOR
Intervention: Exercise and advice
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Activity-focussed physiotherapy
Number of subjects: 41
Study: 12412824

Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 25
Study: 10452208

Group type: EXPERIMENTAL
Intervention: ReliefBand (TENS unit)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 8569136

Group type: EXPERIMENTAL
Intervention: F‐CaP (supplemented formula with Ca 87 mg/dl, P 43 mg/dl)
Number of subjects: 79

Group type: COMPARATOR
Intervention: F (non-supplemented formula with Ca 62 mg/dl, P 36 mg/dl)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: F‐CaP
Number of subjects: 79
Study: 2121109

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day recombinant human growth hormone (rHGH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1104042

Group type: EXPERIMENTAL
Intervention: Catgut layer suture alone
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Catgut layer suture with tension sutures
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Wire sutures alone
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Wire sutures
Number of subjects: 324
Study: 31238700

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin for 90 days
Number of subjects: 4881

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4881
Study: 28663124

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0
Study: 25210141

Group type: EXPERIMENTAL
Intervention: Early BCG vaccination
Number of subjects: 467

Group type: COMPARATOR
Intervention: Usual postponed BCG
Number of subjects: 467
Study: 23414448

Group type: EXPERIMENTAL
Intervention: Foot massage intervention (n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Silent resting control (n=10)
Number of subjects: 19
Study: 21916906

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 2 g/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18355388

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 17167137

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 878

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 878
Study: 14566832

Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 148

Group type: COMPARATOR
Intervention: Noncondom use
Number of subjects: 148
Study: 10933131

Group type: EXPERIMENTAL
Intervention: R-thalidomide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: S-thalidomide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: R-thalidomide and S-thalidomide
Number of subjects: 6
Study: 8743000

Group type: EXPERIMENTAL
Intervention: Perifoveal laser treatment
Number of subjects: 28
Study: 1350935

Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6424498

Group type: EXPERIMENTAL
Intervention: Alfentanil (10 times the dose of fentanyl)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alfentanil and Fentanyl
Number of subjects: 50
Study: 31183588

Group type: EXPERIMENTAL
Intervention: Muscle resistance training exercise program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 120
Study: 29794793

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study: 27492539

Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 124
Study: 24811202

Group type: EXPERIMENTAL
Intervention: MumsQuit
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (information-only website)
Number of subjects: 200
Study: 22728648

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (40 mg/kg for 15 min followed by 10 mg/kg/h during surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (isotonic saline)
Number of subjects: 60
Study: 20639739

Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg) - Paracetamol (500 mg) combination
Number of subjects: 220

Group type: COMPARATOR
Intervention: Etodolac (300 mg) alone
Number of subjects: 220
Study: 16451153

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (32 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermic CPB (36 degrees C)
Number of subjects: 30
Study: 14979681

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) for nine weeks
Number of subjects: 20
Study: 10856145

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 88 microg twice daily
Number of subjects: 451

Group type: COMPARATOR
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 451
Study: 9085723

Group type: EXPERIMENTAL
Intervention: Early prevention program facilitated by occupational therapists (approximately 0.5 hours of intervention once every 8 weeks during the infants' first year of life)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (54 mothers and their infants who did not receive the intervention)
Number of subjects: 55
Study: 1311658

Group type: EXPERIMENTAL
Intervention: Amino acid solution starting on post-natal day 2 (Group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (Group B) starting amino acid solution after day 4
Number of subjects: 18
Study: 3516000

Group type: EXPERIMENTAL
Intervention: Intramuscular meptazinol (1 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular pethidine (1 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 100
Study: 31433479

Group type: EXPERIMENTAL
Intervention: Opt-in simple
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Opt-in detailed
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Opt-out simple
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Opt-out detailed
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Opt-out vs Opt-in interfaces
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Simple vs Detailed forms
Number of subjects: 1246
Study: 30157913

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg) intravenously for 40 min during dural mater incision.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline) administered at the same volume and infusion rate during the same time points.
Number of subjects: 80
Study: 26946617

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of cervus and cucumis polypeptides
Number of subjects: 96

Group type: COMPARATOR
Intervention: Physical therapy and rehabilitation exercises (Control)
Number of subjects: 96
Study: 25203380

Group type: EXPERIMENTAL
Intervention: Orange juice with polyethylene glycol-ascorbic acid
Number of subjects: 107

Group type: COMPARATOR
Intervention: Polyethylene glycol-ascorbic acid
Number of subjects: 107